Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2013 1
2015 1
2016 2
2018 1
2019 4
2020 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.
Schwab N, Schneider-Hohendorf T, Pignolet B, Bucciarelli F, Scandella L, Ciron J, Biotti D, Lebrun-Frenay C, Mathey G, Clavelou P, Pelletier J, Ostkamp P, Meinl I, Windhagen S, Klotz L, Gross CC, Meuth SG, Deisenhammer F, Brassat D, Wiendl H; Best-MS Study Group. Schwab N, et al. Among authors: windhagen s. Neurology. 2019 Sep 17;93(12):550-554. doi: 10.1212/WNL.0000000000008135. Epub 2019 Aug 22. Neurology. 2019. PMID: 31439633 No abstract available.
Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.
Gross CC, Ahmetspahic D, Ruck T, Schulte-Mecklenbeck A, Schwarte K, Jörgens S, Scheu S, Windhagen S, Graefe B, Melzer N, Klotz L, Arolt V, Wiendl H, Meuth SG, Alferink J. Gross CC, et al. Among authors: windhagen s. Neurol Neuroimmunol Neuroinflamm. 2016 Oct 12;3(6):e289. doi: 10.1212/NXI.0000000000000289. eCollection 2016 Dec. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 27766281 Free PMC article.
PML risk stratification using anti-JCV antibody index and L-selectin.
Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H. Schwab N, et al. Among authors: windhagen s. Mult Scler. 2016 Jul;22(8):1048-60. doi: 10.1177/1352458515607651. Epub 2015 Oct 2. Mult Scler. 2016. PMID: 26432858
A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS.
Rolfes L, Pfeuffer S, Ruck T, Windhagen S, Oschlies I, Pavenstädt HJ, Angenendt L, Wiendl H, Krämer J, Meuth SG. Rolfes L, et al. Among authors: windhagen s. Neurol Neuroimmunol Neuroinflamm. 2019 Nov 8;7(1):e638. doi: 10.1212/NXI.0000000000000638. Print 2020 Jan. Neurol Neuroimmunol Neuroinflamm. 2019. PMID: 31704887 Free PMC article. No abstract available.
Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.
Pfeuffer S, Schmidt R, Straeten FA, Pul R, Kleinschnitz C, Wieshuber M, Lee DH, Linker RA, Doerck S, Straeten V, Windhagen S, Pawlitzki M, Aufenberg C, Lang M, Eienbroeker C, Tackenberg B, Limmroth V, Wildemann B, Haas J, Klotz L, Wiendl H, Ruck T, Meuth SG. Pfeuffer S, et al. Among authors: windhagen s. J Neurol. 2019 Jan;266(1):165-173. doi: 10.1007/s00415-018-9117-z. Epub 2018 Nov 16. J Neurol. 2019. PMID: 30446966
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H. Schwab N, et al. Among authors: windhagen s. Neurology. 2013 Sep 3;81(10):865-71. doi: 10.1212/WNL.0b013e3182a351fb. Epub 2013 Aug 7. Neurology. 2013. PMID: 23925765
Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS.
Mäurer M, Dachsel R, Domke S, Ries S, Reifschneider G, Friedrich A, Knorn P, Landefeld H, Niemczyk G, Schicklmaier P, Wernsdörfer C, Windhagen S, Albrecht H, Schwab S; TYPIC Study Investigators. Mäurer M, et al. Among authors: windhagen s. Eur J Neurol. 2011 Aug;18(8):1036-45. doi: 10.1111/j.1468-1331.2010.03313.x. Epub 2010 Dec 29. Eur J Neurol. 2011. PMID: 21199183